$PXMD
Patent approval (Jan 2025)
PaxMedica received its first patent approval for an intranasal formulation of suramin used to treat neurological disorders such as autism.
@ProfessorDman1 ATER is trading like itβs forgotten, but the setup is screaming potential. Clean balance sheet, insider support, and a float that can fly. This feels like early $BINI or $PXMDβbefore volume poured in and everything changed overnight.
$PXMD PAX-101 looking promising for ASD and HAT. FDA meetings seem positive. Potential game-changer in neurological treatments. Watching closely for NDA submissions. Could be big if approvals come through. a closer look at current performance: https://beyondspx.com/article/paxmedica-inc-otc-pxmd-pioneering-treatments-for-neurological-disorders
$PXMD Paxmedica, Inc. (PXMD): A Promising Biopharmaceutical Company Navigating Challenges https://beyondspx.com/article/paxmedica-inc-pxmd-a-promising-biopharmaceutical-company-navigating-challenges
